Dental Care Clinics in Hermosa Beach, CA Accepting Medicare
4 Dental Care Clinics found. Showing 1 - 4
 Hermosa Smiles Dentistry Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1559 Pacific Coast Hwy, Suite 101, Hermosa Beach, CA 90254 Phone: 310-372-7686 Fax: 310-372-7692 |
Quinn Yost Dds Inc Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 1115 Aviation Blvd, Hermosa Beach, CA 90254 Phone: 619-940-8746 |
Robert E Anderson Dmd, Inc Dentist - Endodontics Medicare: Not Enrolled in Medicare Practice Location: 2200 Pacific Coast Hwy Ste 201, Hermosa Beach, CA 90254 Phone: 503-704-3957 |
Donlevy & Estess Oral Surgery Group Dentist - Oral and Maxillofacial Surgery Medicare: Not Enrolled in Medicare Practice Location: 1072 Aviation Blvd, Hermosa Beach, CA 90254 Phone: 310-318-3333 Fax: 310-798-2566 |
News Archive
Study estimates ER costs for hematuria patients at more than $237 million a year
A relatively common urinary tract disorder that can usually be managed in an outpatient setting is adding an estimated $238 million a year to the cost of emergency room visits in the U.S., according to two new studies from Henry Ford Hospital in Detroit.
Researchers have identified a protein in the brain that halts the progression of Alzheimer's
Researchers have identified a protein in the brain that halts the progression of Alzheimer's disease in human brain tissue. The protein, known as "transthyretin," protects brain cells from gradual deterioration by blocking another toxic protein that contributes to the disease process.
Mindfulness could help children avoid obesity
Mindfulness, described as paying attention on purpose and being in the present moment with acceptance, could be an effective way to help children avoid obesity. New research published in the journal Heliyon suggests that the balance in brain networks in children who are obese is different compared to healthy-weight children, making them more prone to over-eating.
FDA approves NDA filing for ibrutinib inhibitor in two B-cell malignancies
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
› Verified 7 days ago